First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies

PLoS Medicine

Volumn 14, Issue 5, 2017, Pages

  Dellicour, Stephanie ^a   Sevene, Esperança ^b,c   McGready, Rose ^d,e   Tinto, Halidou ^f   Mosha, Dominic ^g   Manyando, Christine ^h   Rulisa, Stephen ⁱ   Desai, Meghna ^j   Ouma, Peter ^k   Oneko, Martina ^k   Vala, Anifa ^c   Rupérez, Maria ^c,l   Macete, Eusébio ^c   Menéndez, Clara ^c,l   Nakanabo Diallo, Seydou ^f   Kazienga, Adama ^f   Valéa, Innocent ^f   Calip, Gregory ^m   Augusto, Orvalho ^c   Genton, Blaise ^n,o   Njunju, Eric M ^p   Moore, Kerryn A ^q,r   d’Alessandro, Umberto ^s,t,u   Nosten, Francois ^d,e   ter Kuile, Feiko ^a   Stergachis, Andy ^v   more..

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^c Manhiça Health Research Center   (Mozambique)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CENTRE MURAZ   (Burkina Faso)

^g IFAKARA HEALTH INSTITUTE   (Tanzania)

^h TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

ⁱ UNIVERSITY OF RWANDA   (Rwanda)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k Centre for Global Health Research Medical Research Institute   (Kenya)

^l CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁿ SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^o LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^p Department of Environmental and Plant Sciences   (Zambia)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^s MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^t INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^u LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^v UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; QUININE DERIVATIVE; QUININE;

ADVERSE OUTCOME; AFRICA SOUTH OF THE SAHARA; ARTICLE; CONGENITAL MALFORMATION; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MALARIA; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PRESCRIPTION; PREVALENCE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPONTANEOUS ABORTION; STILLBIRTH; THAILAND; ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; PREGNANCY; SOUTHEAST ASIA;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; AFRICA SOUTH OF THE SAHARA; ARTEMISININS; ASIA, SOUTHEASTERN; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREVALENCE; QUININE; RISK ASSESSMENT; STILLBIRTH;

EID: 85020063127     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002290     Document Type: Article

References (49)

1. World Health OrganizationGuidelines for the treatment of malaria. Third edition. Geneva: World Health Organization; 2015.
2. Clark R, Kumemura M, Makori N, Nakata Y, Bernard F, Harrell A, et al. Artesunate: developmental toxicity in monkeys. Birth Defects Res A Clin Mol Teratol. 2006;76:329.
3. Clark RL, Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol. 2009;28(3):285–96. doi: 10.1016/j.reprotox.2009.05.002 19447170
4. Clark RL, Arima A, Makori N, Nakata Y, Bernard F, Gristwood W, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol. 2008;83(4):418–34. doi: 10.1002/bdrb.20163 18702116
5. Clark RL, Lerman SA, Cox EM, Gristwood WE, White TE, Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol. 2008;83(4):397–406. doi: 10.1002/bdrb.20165 18702118
6. Clark RL, White TE, Clode SA, Gaunt I, Winstanley P, Ward SA, Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol. 2004;71(6):380–94. doi: 10.1002/bdrb.20027 15617018
7. Ejiofor JI, Kwanashie HO, Anuka JA, Some pregnancy-related effects of artemether in laboratory animals. Pharmacology. 2006;77(4):166–70. doi: 10.1159/000094521 16837780
8. El-Dakdoky MH, Evaluation of the developmental toxicity of artemether during different phases of rat pregnancy. Food Chem Toxicol. 2009;47(7):1437–41. doi: 10.1016/j.fct.2009.03.027 19332101
9. Longo M, Zanoncelli S, Torre PD, Riflettuto M, Cocco F, Pesenti M, et al. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol. 2006;22(4):797–810. doi: 10.1016/j.reprotox.2006.08.001 16959470
10. White TE, Clark RL, Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res B Dev Reprod Toxicol. 2008;83(4):407–17. doi: 10.1002/bdrb.20157 18615704
11. Clark RL, Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Defects Res A Clin Mol Teratol. 2012;94(2):61–75. doi: 10.1002/bdra.22868 22125126
12. Li Q, Weina PJ, Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules. 2010;15(1):40–57.
13. World Health Organization, Special Programme for Research & Training in Tropical Diseases. Assessment of the safety of artemisinin compounds in pregnancy. WHO/GMP/TDR/Artemisinin/07.1 Geneva: World Health Organization; 2007.
14. Brabin BJ, An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 1983;61(6):1005–16. 6370484
15. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ, The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg. 1997;91(3):256–62. 9231189
16. Steketee RW, Nahlen BL, Parise ME, Menendez C, The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64(1–2 Suppl):28–35.
17. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):93–104. doi: 10.1016/S1473-3099(07)70021-X 17251080
18. Guyatt HL, Snow RW, The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg. 2001;64(1–2 Suppl):36–44.
19. Burger RJ, van Eijk AM, Bussink M, Hill J, Ter Kuile FO, Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3(1):ofv170. doi: 10.1093/ofid/ofv170 26788543
20. Kioko U, Riley C, Dellicour S, Were V, Ouma P, Gutman J, et al. A cross-sectional study of the availability and price of anti-malarial medicines and malaria rapid diagnostic tests in private sector retail drug outlets in rural Western Kenya, 2013. Malar J. 2016;15(1):359. doi: 10.1186/s12936-016-1404-5 27406179
21. van Geertruyden JP, Thomas F, Erhart A, D’Alessandro U, The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg. 2004;71(2 Suppl):35–40.
22. Huynh BT, Cottrell G, Cot M, Briand V, Burden of malaria in early pregnancy: a neglected problem?Clin Infect Dis. 2015;60(4):598–604. doi: 10.1093/cid/ciu848 25362205
23. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12(5):388–96. doi: 10.1016/S1473-3099(11)70339-5 22169409
24. Moore KA, Simpson JA, Paw MK, Pimanpanarak M, Wiladphaingern J, Rijken MJ, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016;16(5):576–83. doi: 10.1016/S1473-3099(15)00547-2 26869377
25. World Health OrganizationA practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: World Health Organization; 2008.
26. Riley RD, Lambert PC, Abo-Zaid G, Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c221 20139215
27. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–65. doi: 10.1001/jama.2015.3656 25919529
28. Haynes B, Haynes RB, Sackett DL, Guyatt GH, Tugwell P, Forming research questions. In: Clinical epidemiology: how to do clinical practice research. Philadelphia: Lippincott Williams & Wilkins; 2006.
29. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2014 [cited 2017 Mar 28]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
30. Dellicour S, Desai M, Aol G, Oneko M, Ouma P, Bigogo G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective study in western Kenya. Malar J. 2015;14(1):461.
31. Mehta U, Clerk C, Allen E, Yore M, Sevene E, Singlovic J, et al. Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings. BMC Pregnancy Childbirth. 2012;12:89. doi: 10.1186/1471-2393-12-89 22943425
32. Holmes LB, Westgate MN, Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807–12. doi: 10.1002/bdra.20842 21800414
33. Scheuerle A, Tilson H, Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf. 2002;11(6):465–75. doi: 10.1002/pds.726 12426931
34. McGready R, Kang J, Watts I, Tyrosvoutis ME, Torchinsky MB, Htut AM, et al. Audit of antenatal screening for syphilis and HIV in migrant and refugee women on the Thai-Myanmar border: a descriptive study. F1000Res. 2014;3:123. doi: 10.12688/f1000research.4190.2 26664698
35. Tinto H, Sevene E, Dellicour S, Macete E, d’Alessandro U, ter Kuile FO, et al. Assessment of the safety of antimalarial drug use during early pregnancy: protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reprod Health. 2015;12:112. doi: 10.1186/s12978-015-0101-0 26637464
36. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J. 2010;9:249. doi: 10.1186/1475-2875-9-249 20809964
37. Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B, Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J. 2014;13(1):197.
38. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ, Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar J. 2012;11:225. doi: 10.1186/1475-2875-11-225 22770264
39. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Sugiarto P, Tjitra E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS ONE. 2014;9(1):e84976. doi: 10.1371/journal.pone.0084976 24465458
40. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144. doi: 10.1186/1475-2875-10-144 21609473
41. Hill J, D’Mello-Guyett L, Hoyt J, van Eijk AM, ter Kuile FO, Webster J, Women’s access and provider practices for the case management of malaria during pregnancy: a systematic review and meta-analysis. PLoS Med. 2014;11(8):e1001688. doi: 10.1371/journal.pmed.1001688 25093720
42. Sangaré L, Weiss N, Brentlinger P, Richardson B, Staedke S, Kiwuwa M, et al. Patterns of antimalarial drug treatment among pregnant women in Uganda. Malar J. 2011;10:152. doi: 10.1186/1475-2875-10-152 21645402
43. Sinclair D, Donegan S, Isba R, Lalloo DG, Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.
44. Nosten F, McGready R, d’Alessandro U, Bonell A, Verhoeff F, Menendez C, et al. Antimalarial drugs in pregnancy: a review. Curr Drug saf. 2006;1(1):1–15. 18690910
45. Obonyo CO, Juma EA, Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J. 2012;11:2. doi: 10.1186/1475-2875-11-2 22217214
46. Dellicour S, ter Kuile FO, Stergachis A, Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med. 2008;5(9):e187. doi: 10.1371/journal.pmed.0050187 18788893
47. Howards PP, Hertz-Picciotto I, Poole C, Conditions for bias from differential left truncation. Am J Epidemiol. 2007;165(4):444–52. 17150983
48. Margulis AV, Mittleman MA, Glynn RJ, Holmes LB, Hernandez-Diaz S, Effects of gestational age at enrollment in pregnancy exposure registries. Pharmacoepidemiol Drug Saf. 2015;24(4):343–52. doi: 10.1002/pds.3731 25702683
49. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO, Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 2010;7(1):e1000221. doi: 10.1371/journal.pmed.1000221 20126256